Supernus Pharmaceuticals
SUPN
295 hedge funds and large institutions have $1.94B invested in Supernus Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 111 increasing their positions, 97 reducing their positions, and 33 closing their positions.
160% more call options, than puts
Call options by funds: $579K | Put options by funds: $223K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
14% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 97
9% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 33
0% more funds holding
Funds holding: 294 → 295 (+1)
1.65% less ownership
Funds ownership: 107.76% → 106.12% (-1.6%)
10% less capital invested
Capital invested by funds: $2.15B → $1.94B (-$211M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$18.5M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$15.3M |
| 3 |
AC
Armistice Capital
New York
|
+$12.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.3M |
| 5 |
JP Morgan Chase
New York
|
+$7.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$42.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$15.3M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$11.5M |
| 4 |
BlackRock
New York
|
-$11.1M |
| 5 |
ACB
Aristotle Capital Boston
Boston,
Massachusetts
|
-$7.2M |
SUPN Hedge Fund Activity: Q1 2025 in Review
295 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2025, worth a combined $1.94B — down 9.8% from $2.15B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SUPN positions and 33 closed out — a net gain of 3 holders — while 111 added to existing stakes and 97 trimmed.
The largest buyer was Sofinnova Investments, opening a new position worth an estimated $18.5M. The largest seller was Pacer Advisors, cutting an estimated $42.3M.
- 295 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2025, up from 294 in Q4 2024.
- Funds reported $1.94B of Supernus Pharmaceuticals stock for Q1 2025, down 9.8% quarter-over-quarter.
- 36 funds opened new Supernus Pharmaceuticals positions in Q1 2025 and 33 closed out, a net change of +3 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2025 was Sofinnova Investments, an estimated $18.5M added.
- The largest Supernus Pharmaceuticals seller in Q1 2025 was Pacer Advisors, an estimated $42.3M sold.
Based on aggregated 13F filings for Q1 2025.